Generated by AI
Mereo BioPharma Group plc ADR is a biopharmaceutical company focused on developing and commercializing therapeutics for rare diseases and oncology. The company’s current portfolio includes product candidates such as setrusumab for osteogenesis imperfecta, alvelestat for alpha-1 antitrypsin deficiency-associated lung disease, and other clinical-stage programs aimed at addressing serious unmet medical needs. Mereo BioPharma Group plc ADR operates as part of the broader biotechnology sector, where it contributes to the advancement of specialized treatments through clinical development and targeted research. The company is headquartered in London and maintains a presence in both the United Kingdom and the United States, serving patients and medical communities through its pipeline of investigational therapies.
WebsiteOne Cavendish Place
London, W1G 0QF
United Kingdom
The latest articles about MREO.
Detailed price information for Tvardi Therapeutics Inc (TVRD-Q) from The Globe and Mail including charting and trades.
Summary of Nov 17's posts. Generated by AI.
Summary of Aug 11's posts. Generated by AI.
Summary of Aug 11's posts. Generated by AI.
Summary of Oct 12's posts. Generated by AI.
Investors talking about MREO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.